

March 02, 2022

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400 001 Scrip Code: 512529	National Stock Exchange of India Limited Listing Department Exchange Plaza, Bandra-Kurla Complex Bandra (East) Mumbai – 400 051 Symbol: SEQUENT
----------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/ Madam,

Sub: Updates on Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 relating to acquisition of Nourrie Saúde e Nutrição Animal Ltda, through Alivira Saúde Animal Ltda, Brazil, wholly owned subsidiary of the Company

With reference to our announcement dated December 16, 2021, on proposed acquisition of 100% stake in Nourrie Saúde e Nutrição Animal Ltda ('Nourrie') through Alivira Saúde Animal Ltda, Brazil, (erstwhile known as Evance Saude Animal Health Ltda), wholly owned subsidiary of the Company, we would like to inform you that the said transaction has been completed.

On completion of the said transaction, Nourrie has become a Wholly Owned Subsidiary of Alivira Saúde Animal Ltda and consequently of the Company.

A press being issued by the Company is also attached herewith.

We request you to take the above on your record.

Thanking you,

For **Sequent Scientific Limited**



Krunal Shah
Company Secretary & Compliance Officer



SeQuent Scientific Limited

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

Sequent Scientific completes entry into pet segment in Brazil

Concludes acquisition of 100% stake in Nourrie Saúde e Nutrição Animal Ltda

Mumbai, March 2, 2022: SeQuent Scientific Limited (SeQuent), having businesses in animal health sector through its principal operating company “Alivira Animal Health Ltd. (Alivira)”, has completed the acquisition of 100% stake in Nourrie Saúde e Nutrição Animal Ltda (Nourrie) in Brazil. This acquisition has been made through Alivira Saúde Animal Ltda Brazil, a wholly owned subsidiary of Alivira, for a total cash consideration of BRL 27 Million (~USD 5 Million).

SeQuent had originally announced signing of the binding agreement to acquire Nourrie on 16th December 2021. The conclusion of Nourrie’s acquisition marks an important milestone in Sequent 2.0 strategy of establishing presence in Brazil’s pet market, the fastest growing segment. Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 Billion, growing annually at ~16%.

The addition of Nourrie’s business has nearly doubled the product portfolio available to Alivira for commercialization in Brazil, with additions in both the nutraceutical and therapeutic product categories. Nourrie also brings a strong pipeline of 20 products under development, 12 of which are planned for launch in the next fiscal.

The acquisition also provides Alivira complete control over the value-chain of Transuin, a Ractopamine based swine product currently manufactured at Nourrie, which is at present the 3rd largest product in Alivira Brazil’s portfolio. With access to Alivira’s own API manufactured in the USFDA approved plant at Vizag, and extension of product range with upcoming registration approvals, Alivira intends to fast-track growth for Transuin franchise in both Brazil and other Latam markets. The expansion of swine and poultry segment will be further catalysed with nearly 5 new product launches expected in the near term.

Consequent to the oversight of Alivira management, Nourrie’s pet business outlook has been promising, with monthly revenues having grown by 50%+ in February 2022, compared to those at the time of acquisition announcement in December 2021. Alivira already has an established track-record of performance in Brazil, with the local operations growing 5-fold at a CAGR of 57% over last 5 years. Brazil has emerged as the third largest market for Alivira, next only to Spain and Turkey.

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) is India’s largest and amongst the ‘Top 20’ global animal health companies, backed by global investment firm ‘The Carlyle Group’ as promoter. The company generated annual revenues of ~\$200 Mn in FY21 with ~2/3rd revenues from regulated markets. The company has 8 manufacturing facilities across Europe, Turkey, Brazil & India with the Vizag site being India’s only USFDA approved dedicated veterinary API facility.

For details, feel free to contact:

Tushar Mistry

Chief Financial Officer
Tel: +91 22 4111 4717
tushar.m@sequent.in

Abhishek Singhal

Investor Relations Consultants
abhishek.s@sequent.in

Registered Office

301/A, ‘Dosti Pinnacle’, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Maharashtra, India

CIN: L99999MH1985PLC036685

BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Website: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.